Citadel Advisors’s VanEck Biotech ETF BBH Stock Holding History

Citadel Advisors’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$264K	Buy	+1,300	New	+$244K	﹤0.01%	11407

Other funds holding BBH

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

MIM

Miller Investment Management West Conshohocken, Pennsylvania $1.09B AUM 18.31% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

CCA

Conservest Capital Advisors Wynnewood, Pennsylvania $1.26B AUM 24.75% 1-Year Est. Return

BFG

Bleakley Financial Group Fairfield, New Jersey $7.85B AUM 31.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Citadel Advisors's BBH Position: Q2 2026 in Review

Citadel Advisors reduced its VanEck Biotech ETF (BBH) stake by 43% in Q2 2026, selling an estimated $762K and leaving 5,463 shares worth $1.11M. The position accounts for ﹤0.01% of the portfolio, ranked #7947.

Citadel Advisors first reported a position in BBH in Q2 2014 and has held it in 35 quarters since. The position peaked at $6.05M in Q1 2019. 110 funds tracked by Wall St. Rank hold BBH as of Q2 2026.

Citadel Advisors held 5,463 shares of VanEck Biotech ETF worth $1.11M as of Q2 2026.
Citadel Advisors sold 4,051 VanEck Biotech ETF shares in Q2 2026, an estimated $762K.
VanEck Biotech ETF made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #7947 holding.
Citadel Advisors first reported a position in VanEck Biotech ETF in Q2 2014 and has held it in 35 quarters since.
Citadel Advisors's VanEck Biotech ETF position peaked at $6.05M in Q1 2019.
110 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.